Brightine for Cholangiocarcinoma and Pancreatic Cancers
Boehringer Ingelheim is studying BI 907828, an investigational MDM2-p53 antagonist, for advanced biliary tract or pancreatic cancer.
Boehringer Ingelheim is studying BI 907828, an investigational MDM2-p53 antagonist, for advanced biliary tract or pancreatic cancer.